Maccura Biotechnology Co.Ltd (300463.SZ) Stock

About Maccura Biotechnology Co.Ltd

Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.

Maccura Biotechnology Co.Ltd is led by CEO Wu Mingjian, employs 2,875 people, headquartered in Chengdu, CN, publicly traded since 2015.

over the past 52 weeks the stock has ranged between $7.87 and $14.20, and currently trades 35.2% below its 52-week high.

Official website: www.maccura.com

Maccura Biotechnology Co.Ltd (300463.SZ) — frequently asked questions